Interspecies comparison of the pharmacokinetics and oral bioavailability of 99-357, a potent synthetic trioxane antimalarial compound.
The pharmacokinetic data obtained in lower animals is of considerable importance in drug discovery and development. The objective of the present study was to generate in vitro and in vivo preclinical pharmacokinetic data of 99-357, a synthetic trioxane antimalarial, in rats and rabbits and to scale-up the data in order to apply for further studies. The pharmacokinetic profile of 99-357 was investigated after both intravenous and oral dose in rats and rabbits. Oral studies were carried out at three dose levels 6, 12 and 24mg/kg in rats while in rabbit only one dose level was selected. Both compartmental and non-compartmental approaches were used to calculate the pharmacokinetic parameters following intravenous and oral doses in both the species. The clearance in rat and rabbit was 45-57% and 60-67% respectively of hepatic blood flow. The plasma protein binding in rats was approximately 75%. In vitro studies showed high RBC partitioning and low to moderate hepatic clearance. Linearity was observed in terms of dose and AUCs suggesting linear pharmacokinetics at the dose levels studied in rats. The oral bioavailability of compound 99-357 in rat and rabbit at 12mg/kg dose level was comparable and 39% and 41% respectively.
Singh
Rajendra Pratap
RP
Pharmacokinetics & Metabolism Division, Central Drug Research Institute, CSIR, Lucknow, India.
Gupta
Ram Chandra
RC
Singh
Shio Kumar
SK
D000284:Administration, Oral; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D037621:Artemisinins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D006207:Half-Life; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity
C499892:99-357 compound; D000962:Antimalarials; D037621:Artemisinins